Compare Deckers Outdoor Corp (DECK) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Johnson & Johnson — how do they compare? Deckers Outdoor Corp trades at $82.94 (market cap $11.24B), while Johnson & Johnson trades at $261.2 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 55× Deckers Outdoor Corp's market cap, and Johnson & Johnson pays a 2.09% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Johnson & Johnson for 129 Days on average.
| DECK | JNJ | |
|---|---|---|
Market Cap | $11.24B | $618.09B |
Volume | 3,010,945 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $278.43 |
52-Week Low | $77.51 | $186.00 |
Typical Hold Time | 71 Days | 129 Days |
Enterprise Value | $10.11B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers Outdoor (DECK) trades at $83.32, up 3.66% with strong momentum as technical indicators show bullish signals. The company demonstrates robust fundamentals with revenue growing from $3.2B in 2022 to $5.0B in 2025, net profit margin expanding to 19.37%, and attractive valuation metrics including P/E of 11.74. Recent earnings beats and strong HOKA/UGG brand performance support positive sentiment.
Outlook remains positive with 44.65% analyst buy ratings and $117.13 consensus price target suggesting 40% upside potential. Key risks include competitive pressures in footwear sector and potential consumer spending slowdown. The stock presents a compelling growth opportunity with strong cash flow generation and expanding margins.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
